FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ. Heiss BL, Chang E, Joeng HK, Fiero MH, et al. Clin Cancer Res 2025;31:4223-4229.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Heiss BL, Chang E, Joeng HK, Fiero MH, et al. FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ. Clin Cancer Res 2025;31:4223-4229.
PMID: 40824697